I got it via Webull. I filtered the newsfeed to show only PR and filings. These letters btwn the SEC and SBFM popped up a few days ago. The letters were from back in May but just became available 3 days ago.
I’ll copy and paste them here:
“Sunshine Biopharma, Inc.
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
May 18, 2022
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re: Sunshine Biopharma, Inc.
Registration Statement on Form S-3
Filed May 10, 2022
File No. 333- 264830
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sunshine Biopharma, Inc. hereby respectfully requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time, May 20, 2022, or as soon as practicable thereafter.
Very truly yours,
Sunshine Biopharma, Inc.
By: /s/ Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chief Executive Officer”
————————————————————-
“United States securities and exchange commission logo
May 18, 2022
Steve Slilaty
Chief Executive Officer
Sunshine Biopharma, Inc
6500 Trans-Canada Highway, 4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
Re: Sunshine Biopharma,
Inc
Registration
Statement on Form S-3
Filed May 10, 2022
File No. 333-264830
Dear Dr. Slilaty:
This is to advise you that we have not reviewed and will not
review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Alyssa
Wall at 202-551-8106 with any questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc: Jeff Cahlon”
